SCHEMBL1923337

SCHEMBL1923337

CCn1c(=O)cc[nH]c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 3/20 0.39
LMNA P02545 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38
NFKB1 P19838 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 2/20 0.37
GAA P10253 2/20 0.37
ADORA2A P29274 3/20 0.36
PDE4A P27815 2/20 0.36
PDE4B Q07343 2/20 0.36
PDE4C Q08493 2/20 0.36
PDE4D Q08499 2/20 0.36
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9118472 0.83 KDM4E (0.39) ALDH1A1BLMSMN1; SMN2KDM4EGAA
SCHEMBL4348692 0.82 ADRA1D (0.37) CYP1A2MEN1KMT2ABRD4TAF1
SCHEMBL6864608 0.80 TDP1 (0.44) ALDH1A1TSHRADORA2APDE4APDE4B
SCHEMBL8656963 0.79 ALDH1A1 (0.45) CYP1A2MEN1KMT2AALDH1A1LMNA
SCHEMBL8952367 0.79 ADRA1D (0.33) CYP1A2MEN1KMT2AALDH1A1
SCHEMBL7099892 0.79 ADORA2A (0.47) ALDH1A1CYP3A4TSHRKDM4EGAA
SCHEMBL8377755 0.78 TYMP (0.32)
SCHEMBL10618040 0.78 ADRA1D (0.33)
SCHEMBL8377767 0.78 ADRA1D (0.31)
SCHEMBL4372132 0.78 CCR8 (0.32) KMT2AALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230273456-A1 OPTICALLY ACTIVE DEVICES JOHNSON & JOHNSON SURGICAL VISION INC (US) 2023-08-31 US disclosed
US-20230273456-A1 OPTICALLY ACTIVE DEVICES JOHNSON & JOHNSON SURGICAL VISION INC (US) 2023-08-31 US disclosed
WO-2022012798-A1 OPTICALLY ACTIVE DEVICES MERCK PATENT GMBH (DE) 2022-01-20 WO disclosed
US-10378011-B2 Oligonucleotide KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-08-13 US disclosed
CN-109715802-A Oligonucleotide probe and use thereof 卡里斯科学公司 2019-05-03 CN disclosed
WO-2017214145-A1 METHODS FOR DETECTING OLIGONUCLEOTIDES IN A SAMPLE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-12-14 WO disclosed
CN-106661611-A Method for detecting Trichomonas vaginalis 西菲伊德公司 2017-05-10 CN disclosed
US-20150376611-A1 OLIGONUCLEOTIDE KYOWA KIRIN CO., LTD. (JP) 2015-12-31 US disclosed
CN-101450954-B Nucleotide analogs and use thereof, and medicament composition containing nucleotide analogs UNIV PLA 2ND MILITARY MEDICAL 2013-05-08 CN disclosed
EP-2576786-A1 HIGH-AFFINITY NUCLEIC ACID APTAMERS AGAINST SCLEROSTIN PROTEIN The University of Hong Kong (CN) 2013-04-10 EP disclosed
CN-1436082-A 3 '-or 2' -hydroxymethyl substituted nucleoside derivatives for the treatment of hepatitis virus infections PHARMASSET LTD (BB) 2003-08-13 CN disclosed
US-6268373-B1 ENZYME INHIBITORS EURO-CELTIQUE S.A. (LU) 2001-07-31 US disclosed
US-6025361-A EFFECTIVE PDE IV INHIBITORS, ASTHMA EURO-CELTIQUE, S.A. (LU) 2000-02-15 US disclosed
US-5977119-A Trisubstituted thioxanthines EURO-CELTIQUE, S.A. (LU) 1999-11-02 US disclosed
EP-0799040-A4 TRISUBSTITUTED THIOXANTHINES EURO CELTIQUE SA (LU) 1998-04-01 EP disclosed
EP-0799040-A1 TRISUBSTITUTED THIOXANTHINES Euroceltique S.A. (LU) 1997-10-08 EP disclosed
WO-1996018400-A1 TRISUBSTITUTED THIOXANTHINES EURO-CELTIQUE, S.A. (LU) 1996-06-20 WO disclosed
US-RE34201-E Analgesics ANAQUEST, INC. (US) 1993-03-23 US disclosed
US-5053411-A Analgesics ANAQUEST, INC. (US) 1991-10-01 US disclosed
EP-0396282-A2 N-aryl-N-[4-(heterocyclicalkyl) piperidinyl]amides and pharmaceutical compositions and methods employing such compounds BOC, INC. (US) 1990-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10378011-B2 Oligonucleotide HNRNPA3, AGO2, RBM3 CYP1A2 4285/4885MEN1 3657/4885KMT2A 464/4885
US-20230273456-A1 OPTICALLY ACTIVE DEVICES PDE6C, PDE6D, PDE6A CYP1A2 2773/4885MEN1 3047/4885KMT2A 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.